Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study - Top-Institutions - MDSpire

Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study

  • By

  • John A. Snowden

  • Sam H. Ahmedzai

  • Angela Cox

  • David A. Cairns

  • A. John Ashcroft

  • Cathy Williams

  • Jamie D. Cavenagh

  • Anna Hockaday

  • Julia M. Brown

  • Ian W. Brock

  • Treen C. M. Morris

  • Gordon Cook

  • June 29, 2022

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology-Oncology
    • Pain Medicine
    • Genomics

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology-Oncology
    • Pain Research
    • Genomic Medicine

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology-Oncology
    • Pain Management
    • Genetics

  • #4

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, TX

    Key Differentiators

    • Hematology-Oncology
    • Pain Genetics
    • Pharmacogenomics

  • #5

    University of Cambridge
    University of Cambridge

    Cambridge, UK

    Key Differentiators

    • Hematology
    • Pain Genetics
    • Cancer Genomics

Original Source(s)

Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study

  • by John A. Snowden, Sam H. Ahmedzai, Angela Cox, David A. Cairns, A. John Ashcroft, Cathy Williams, Jamie D. Cavenagh, Anna Hockaday, Julia M. Brown, Ian W. Brock, Treen C. M. Morris, Gordon Cook

  • June 29, 2022

Related Content

Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders

A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.